Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Clin Pharmacol Ther. 2019 Nov 1;107(3):563–570. doi: 10.1002/cpt.1641

Figure 2.

Figure 2.

Percent of unique patients avoiding subtherapeutic voriconazole (VCZ) concentrations, defined as a trough less than 1 μg/mL. The Fisher’s exact test compared groups stratified by CYP2C19 diplotype and dosage. Unique patients avoiding subtherapeutic VCZ concentrations were also compared between CYP2C19 rapid metabolizers receiving the standard VCZ dosage (200 mg twice daily [BID]) and the interventional dosage (300 mg BID).